NCM·Healthcare·$113M·#469 / 520 in Healthcare
CRDF Cardiff Oncology, Inc.
20HIGH RISK
CATEGORY BREAKDOWN
GROWTH0
QUALITY0
STABILITY39
VALUATION0
GOVERNANCE57
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-13.2%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
N/A
0
> 50% strong
Cash Runway
Months of cash at current burn rate
6 months
9
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
1.8%
99
< 25% strong
Price / Sales
Market cap relative to trailing revenue
190.8x
0
< 3x strong
Rule of 40
Growth rate plus operating margin
-8270
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
5.9%
45
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
+2.8%
83
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE CRDF WITH…
OR QUICK-COMPARE SECTOR PEERS
SCORE ALERT
Get notified when CRDF's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.